Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 307-055-2 | CAS number: 97489-15-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Repeated dose toxicity: dermal
Administrative data
- Endpoint:
- short-term repeated dose toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1975
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: see 'Remark'
- Remarks:
- No guideline study and non-GLP but performed according to scientific standards at time of performance. Acceptable based on nowadays existing guidlines and standards. Well performed and documented. Reliability declaration regarding procedures and performance available.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 975
- Report date:
- 1975
Materials and methods
Test guideline
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- Subacute (4 and 5 week exposure periods) dermal toxicity study
- GLP compliance:
- no
- Remarks:
- not required at time of performance
- Limit test:
- no
Test material
- Reference substance name:
- Sulfonic acids, C14-17-sec-alkane, sodium salts
- EC Number:
- 307-055-2
- EC Name:
- Sulfonic acids, C14-17-sec-alkane, sodium salts
- Cas Number:
- 97489-15-1
- Molecular formula:
- H3C-(CH2)m-CH-(SO3Na)-(CH2)n-CH3
- IUPAC Name:
- Sulfonic acids, C14-17-sec-alkane, sodium salts
- Reference substance name:
- Hostapur SAS 60
- IUPAC Name:
- Hostapur SAS 60
- Details on test material:
- - Name of test material (as cited in study report): Hostapur SAS 60
- Structural formula attached as image file (if other than submission substance): see Fig.
- Physical state: slurry
- Analytical purity: 60%
- Composition of test material, percentage of components: 60% Hostapur SAS 93, water
- Isomers composition: n.a.
- Purity test date: 1974-09-03
- Lot/batch No.: no data
- Expiration date of the lot/batch: 1976-09-01
- Radiochemical purity (if radiolabelling): n.a.
- Specific activity (if radiolabelling): n.a.
- Locations of the label (if radiolabelling): n.a.
- Expiration date of radiochemical substance (if radiolabelling): n.a.
- Stability under test conditions: stability and homogeneity guaranteed
- Storage condition of test material: in darkness at room temperature
- Other:
Constituent 1
Constituent 2
Test animals
- Species:
- mouse
- Strain:
- CD-1
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River U.K.
- Age at study initiation: young adult
- Weight at study initiation: 16 - 18 g
- Fasting period before study: no
- Housing: polypropylene cages
- Diet (e.g. ad libitum): ad libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period: 6 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21 +/- 2 °C
- Humidity (%): no data
- Air changes (per hr): 15
- Photoperiod (hrs dark / hrs light): 12 hours
Administration / exposure
- Type of coverage:
- open
- Vehicle:
- water
- Details on exposure:
- TEST SITE
- Area of exposure: 4 cm2
- % coverage: 100
- Type of wrap if used: n.a.
- Time intervals for shavings or clipplings: 2 - 3 days
REMOVAL OF TEST SUBSTANCE
- Washing (if done): n.a.
- Time after start of exposure: n.a.
TEST MATERIAL
- Concentration (if solution): 0, 0.1, 0.5 (increasing to 8.0 up to 16.0) and 1.0 (increasing to 2.0 up to 32) % (w/v)
- Constant volume or concentration used: yes (0.1 mL per animal)
- For solids, paste formed: n.a.
VEHICLE
- Justification for use and choice of vehicle (if other than water): water
- Amount(s) applied (volume or weight with unit): n.a.
- Concentration (if solution): n.a.
- Lot/batch no. (if required): n.a.
- Purity: n.a.
USE OF RESTRAINERS FOR PREVENTING INGESTION: no data - Analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- 4 and 5 weeks according to experimental group
- Frequency of treatment:
- 5 days/week
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0.1 mL of 0.1 up to 32 % (w/v) test solutions
Basis:
nominal per unit area
- No. of animals per sex per dose:
- 25 female animals per group
- Control animals:
- yes
- Details on study design:
- - Dose selection rationale: expert judgement
- Rationale for animal assignment (if not random): random
- Rationale for selecting satellite groups: n.a.
- Post-exposure recovery period in satellite groups: n.a.
- Section schedule rationale (if not random): random
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: daily
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: daily
DERMAL IRRITATION (if dermal study): Yes
- Time schedule for examinations: daily
BODY WEIGHT: Yes
- Time schedule for examinations: weekly
FOOD CONSUMPTION:
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No data
WATER CONSUMPTION: Yes
- Time schedule for examinations: daily
OPHTHALMOSCOPIC EXAMINATION: No data
HAEMATOLOGY: No data
CLINICAL CHEMISTRY: No data
URINALYSIS: No data
NEUROBEHAVIOURAL EXAMINATION: No data
OTHER: - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: No data - Other examinations:
- Organ weight analysis
- Statistics:
- As appropriate
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Dermal irritation:
- effects observed, treatment-related
- Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Ophthalmological findings:
- not specified
- Haematological findings:
- not specified
- Clinical biochemistry findings:
- not specified
- Urinalysis findings:
- not specified
- Behaviour (functional findings):
- not specified
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- not specified
- Histopathological findings: neoplastic:
- not specified
- Details on results:
- OTHER FINDINGS: Repeated dermal treatment with test concentrations of 16% and higher led to irritative skin changes. Secondary responses due to
the inflammatory and infective condition affecting the skin at higher test concentrations included sligtly increased spleen weights.
Effect levels
- Dose descriptor:
- NOEL
- Effect level:
- ca. 500 other: mg/kg bw / day (calculated)
- Sex:
- male/female
- Basis for effect level:
- other: NOEL is based on local irritation / inflammation at treated skin sites
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- Concentrations up to 8% were tolerated without any signs of intoxication.
- Executive summary:
A subacute dermal toxicity study with sec-alkane sulfonate-sodium salts SAS (60%) was performed in CD-1 mice using aqueous solutions of the test material at different concentrations. 4 groups of 25 female mice were topically administered 0.1 mL of 0% (control), o.1% (group 2), 0.5% (group 3) or 1% (group 4) sec-alkane sulfonate-sodium salts SAS (60%) (w/v). After 3 weeks of exposure the concentration applied to group 3 was increased to 8% and after 4 weeks to 16% (w/v). The concentration of the test solution applied to group 4 was increased after one week to 2% and after 3 weeks to 32% (w/v). Treatment was continued 5 days per week for 4 consecutive weeks in the case of groups 2 and 4, and for 5 weeks in groups 1 and 3. Encrustation, skin thickening, erythema and skin sloughing were observed at the treated skin sites in all mice within two days of commencement of treatment with solutions containing 32% (w/v). Mice given 16% showed skin thickening after one week of treatment. Mice treated with solutions containing 8% sec-alkane sulfonate-sodium salts SAS (60%) and below showed no detectable reactions at the exposed skin sites. Weight losses, without concomitant reduction of food intake, were seen in all mice receiving 32% in the first week of treatment. However, a return to normal growth was observed during the second week of exposure at this level. Mice dermally treated at 8% or below showed no weight retardation. Organ weight analysis showed increased absolute and relative spleen weights in mice given 32%. This was considered a secondary response to the inflammatory and infective condition affecting the skin. Absolute and relative weights of liver and kidneys in mice given 32%, and all three organs at lower levels of administration were unaltered by the treatment. In summary, the NO(A)EL in mice for local effects calculated on body weight is approximately 500 mg/kg body weight per day whereas for systemic effects a NO(A)EL of 1000 mg/kg body weight per day can be assumed.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
